Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more) Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Collegium Pharmaceutical Inc COLL

Healthcare
Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed... see more

Recent & Breaking News (NDAQ:COLL)

Collegium to Present at the 42nd Annual Deutsche Bank Healthcare Conference

GlobeNewswire April 20, 2017

Collegium Announces Appointment of Steven Passik, PhD, as Vice President, Scientific Affairs, Education and Policy

GlobeNewswire April 4, 2017

Collegium Announces Expanded Managed Care Coverage for Xtampza ER for Medicare Part D Patients

GlobeNewswire April 3, 2017

Collegium to Present at the 16th Annual Needham Healthcare Conference

GlobeNewswire March 28, 2017

Collegium Announces Scientific Presentation at American Academy of Pain Medicine 2017 Meeting

GlobeNewswire March 16, 2017

Collegium Reports Fourth Quarter Financial Results and Provides Corporate Update

GlobeNewswire March 9, 2017

Collegium to Host Conference Call to Discuss 2016 Financial Results and Provide Corporate Update

GlobeNewswire February 28, 2017

Collegium Announces Positive Topline Results of Human Abuse Potential Clinical Trial Evaluating the Oral Abuse of Xtampza ER

GlobeNewswire February 1, 2017

Collegium Announces Underwriters’ Exercise of Option to Purchase Additional Shares

GlobeNewswire November 29, 2016

Independent Review of Xtampza® ER Published in Peer-Reviewed Medical Journal

GlobeNewswire November 21, 2016

Collegium to Present at Upcoming Investor Conferences

GlobeNewswire November 11, 2016

Collegium Reports Third Quarter Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2016

Collegium to Host Conference Call to Discuss Third Quarter 2016 Financial Results and Provide Corporate Update

GlobeNewswire November 2, 2016

Collegium Prices Public Offering of $80 million of Common Stock

GlobeNewswire October 26, 2016

Collegium Announces Proposed Public Offering of Common Stock

GlobeNewswire October 25, 2016

Collegium Submits Supplemental New Drug Submission to FDA for Xtampza® ER

GlobeNewswire October 5, 2016

Collegium Submits New Drug Submission to Health Canada for Xtampza® ER, an Analgesic with Abuse-Deterrent Properties for the Treatment of Chronic Pain

GlobeNewswire October 3, 2016

18 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  October 3, 2016

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  September 30, 2016

Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER

GlobeNewswire September 29, 2016